Postoperative Assessment of Platelet-Rich Plasma and Platelet-Rich Fibrin in Temporomandibular Joint Surgery

ConditionTemporomandibular Joint Disorders

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-75

SponsorJingping Wang, MD, Ph.D.

About this trial

The goal of this observational study is to evaluate postoperative outcomes following temporomandibular joint (TMJ) surgery and to compare the effectiveness of intraoperative platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) injections in patients with temporomandibular joint disorders.

The study includes adult patients who underwent TMJ surgery and received either PRP or PRF intraoperatively. The main questions this study aims to answer are:

Whether intraoperative PRP or PRF injection is associated with differences in postoperative pain intensity and recovery.

Whether PRP and PRF differ in their effects on postoperative jaw function, including maximum mouth opening and joint symptoms.

If there is a comparison group: Researchers will compare patients who received intraoperative PRP with those who received intraoperative PRF to assess differences in postoperative pain, functional outcomes, and joint-related symptoms.

Participants will:

Have their existing medical records reviewed retrospectively.

Provide postoperative outcome data derived from routine clinical follow-up, with no prospective recruitment or intervention.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

The study population consists of adult patients aged 18 to 75 years who underwent unilateral or bilateral temporomandibular joint arthroscopy at a single institution. All patients received intraoperative intra-articular injection of platelet-rich plasma (PRP) or platelet-rich fibrin (PRF) as part of routine clinical care. This is a retrospective observational study based on review of existing medical records, with no prospective recruitment or intervention.

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

700 Participants

are grouped into 3 trial groups

Group A: Group 1 - Platelet-Rich Plasma injection therapy group

Group B: Group 2 - Platelet-Rich Fibrin injection therapy group

Group C: Group 3 - non injection therapy group

Trial outcomes

Primary outcomes

pain intensity

The primary endpoint of the study is the change in pain intensity from baseline to 6 months post-surgery.

Time frame

from baseline to 6 months post-surgery.

Secondary outcomes

maximum unassisted opening (MMO)

collect data about maximum unassisted opening (MMO)

Time frame

baseline and various follow-up times in 6 months.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Jingping Wang, MD, Ph.D.

Lead sponsor

Massachusetts General Hospital

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: